SCHEMBL6987790

SCHEMBL6987790

C=Cc1ccc(C(=O)NCCC(C)CC(=O)NC2(C)C(=O)COC2C)cc1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
PLD2 O14939 1/20 0.35
PLD1 Q13393 1/20 0.35
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NAMPT P43490 1/20 0.32
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
DRD3 P35462 1/20 0.31
GAA P10253 1/20 0.31
THRB P10828 1/20 0.31
TTK P33981 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985875 0.88 LMNA (0.40) RAB9ANPC1SMN1; SMN2GAATHRB
SCHEMBL6989326 0.87 RAB9A (0.38) RAB9ANPC1SMN1; SMN2GAA
SCHEMBL6985259 0.86 HDAC1 (0.40) RAB9ANPC1SMN1; SMN2NAMPTDRD2
SCHEMBL6985955 0.86 NAMPT (0.37) RAB9ANPC1NAMPT
SCHEMBL6987802 0.84 KMT2A (0.41) RAB9ANPC1SMN1; SMN2
SCHEMBL6986218 0.83 TRPV1 (0.40)
SCHEMBL6986287 0.82 CHRM4 (0.39) RAB9ANPC1SMN1; SMN2DRD2DRD4
SCHEMBL6990430 0.81 GCGR (0.41) DRD2DRD3
SCHEMBL6752408 0.77 TAS1R3 (0.53) TAS1R3TAS1R1
SCHEMBL6988433 0.75 TAS1R3 (0.35) TAS1R3TAS1R1PLD2PLD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1362042-A1 CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES Amura Therapeutics Limited (GB) 2003-11-19 EP disclosed
WO-2002057249-A1 CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LIMITED (GB) 2002-07-25 WO disclosed